The Pediatric Challenge - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Pediatric Challenge
Can microdosing make medicines safer and more effective for children?


Pharmaceutical Technology
Volume 35, Issue 6, pp. 14


Stephanie Sutton
Medicines are often prescribed to children even though they have only been designed and tested in adults because of the ethical and practical issues associated with conducting pediatric trials. However, children's drug kinetics, metabolism, and dynamics can vary substantially compared with adults, which is why a consortium in Europe is exploring the potential of microdosing to obtain pharmacokinetic data that could be used to study new drugs. In particular, the consortium will be looking to improve drug development for infants (children aged 0–2 years) by using accelerator mass spectroscopy to overcome the main microdosing issue of measuring extremely low concentrations of drug candidates in tiny blood samples.

I found out more about this project during an interview with Wouter Vaes, who is responsible for early clinical development at the TNO in The Netherlands, one of the institutes involved in the consortium.

"Microdosing is one of the best tools that industry can choose to obtain human data at early stage in development," said Vaes. "Eventually, we expect that microdosing will be used to derive kinetic and metabolic information for all age groups at the same time."

If successful, the project could encourage greater uptake of microdosing. Microdosing provides data about a drug's pharmacokinetics and pharmacodynamics in humans at an early stage of development. With the potential to be a valuable drug development tool, microdosing is definitely a technology to keep an eye on.

Stephanie Sutton is an associate editor of Pharmaceutical Technology.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here